The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population—A Narrative Review
Abstract
:1. Introduction
2. Breast Growth
3. Mental State
4. Lactation
5. Prostate Cancer
6. Thrombosis
7. Breast Cancer
8. Brain
9. Other Organs
10. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- National Academies of Sciences, Engineering, and Medicine. Measuring Sex, Gender Identity, and Sexual Orientation; Becker, T., Chin, M., Bates, N., Eds.; National Academies Press (US): Washington, DC, USA, 9 March 2022. [Google Scholar] [PubMed]
- Beek, T.F.; Cohen-Kettenis, P.T.; Kreukels, B.P. Gender incongruence/gender dysphoria and its classification history. Int. Rev. Psychiatry 2016, 28, 5–12. [Google Scholar] [CrossRef] [PubMed]
- Cooper, K.; Russell, A.; Mandy, W.; Butler, C. The phenomenology of gender dysphoria in adults: A systematic review and meta-synthesis. Clin. Psychol. Rev. 2020, 80, 101875. [Google Scholar] [CrossRef] [PubMed]
- Ellis, S.A.; Dalke, L. Midwifery Care for Transfeminine Individuals. J. Midwifery Womens Health 2019, 64, 298–311. [Google Scholar] [CrossRef] [PubMed]
- Coleman, E.; Radix, A.E.; Bouman, W.P.; Brown, G.R.; de Vries, A.L.C.; Deutsch, M.B.; Ettner, R.; Fraser, L.; Goodman, M.; Green, J.; et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int. J. Transgend Health 2022, 23 (Suppl. S1), S1–S259. [Google Scholar] [CrossRef]
- Nounu, A.; Kar, S.P.; Relton, C.L.; Richmond, R.C. Sex steroid hormones and risk of breast cancer: A two-sample Mendelian randomization study. Breast Cancer Res. 2022, 24, 66. [Google Scholar] [CrossRef]
- El-Hefnawy, T.; Huhtaniemi, I.T. Progesterone and testicular function. The Aging Male 2009, 2, 240–245. [Google Scholar] [CrossRef]
- Muneyyirci-Delale, O.; Dalloul, M.; Nacharaju, V.L.; Altura, B.M.; Altura, B.T. Serum ionized magnesium and calcium and sex hormones in healthy young men: Importance of serum progesterone level. Fertil. Steril. 1999, 72, 817–822. [Google Scholar] [CrossRef]
- Oettel, M.; Mukhopadhyay, A.K. Progesterone: The forgotten hormone in men? Aging Male 2004, 7, 236–257. [Google Scholar] [CrossRef]
- Taraborrelli, S. Physiology, production and action of progesterone. Acta Obstet. Gynecol. Scand. 2015, 94 (Suppl. S161), 8–16. [Google Scholar] [CrossRef]
- Azeez, J.M.; Susmi, T.R.; Remadevi, V.; Ravindran, V.; Sasikumar Sujatha, A.; Ayswarya, R.N.S.; Sreeja, S. New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling. Am. J. Cancer Res. 2021, 11, 5214–5232. [Google Scholar]
- Peltier, M.R.; Sofuoglu, M. Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review. CNS Drugs 2018, 32, 421–435. [Google Scholar] [CrossRef] [PubMed]
- Miller, V.T.; LaRosa, J.; Barnabei, V.; Kessler, C.; Levin, G.; Smith-Roth, A.; Griffin, M.; Stoy, D.B.; Bush, T.; Zacur, H.; et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273, 199–208. [Google Scholar] [CrossRef]
- Gillet, J.Y.; Andre, G.; Faguer, B.; Erny, R.; Buvat-Herbaut, M.; Domin, M.A.; Kuhn, J.M.; Hedon, B.; Drapier-Faure, E.; Barrat, J.; et al. Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study. Maturitas 1994, 19, 103–115. [Google Scholar] [CrossRef] [PubMed]
- Hargrove, J.T.; Maxson, W.S.; Wentz, A.C.; Burnett, L.S. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet. Gynecol. 1989, 73, 606–612. [Google Scholar]
- Harman, S.M.; Black, D.M.; Naftolin, F.; Brinton, E.A.; Budoff, M.J.; Cedars, M.I.; Hopkins, P.N.; Lobo, R.A.; Manson, J.E.; Merriam, G.R.; et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann. Intern. Med. 2014, 161, 249–260. [Google Scholar] [CrossRef]
- Moorjani, S.; Dupont, A.; Labrie, F.; De Lignieres, B.; Cusan, L.; Dupont, P.; Mailloux, J.; Lupien, P.J. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J. Clin. Endocrinol. Metab. 1991, 73, 373–379. [Google Scholar] [CrossRef]
- Marra, C.; Penati, C.; Ferrari, L.; Cantu, M.G.; Bargossi, L.; Fruscio, R. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: Response rate to different doses. Gynecol. Endocrinol. 2014, 30, 899–901. [Google Scholar] [CrossRef]
- Wierckx, K.; Gooren, L.; T’Sjoen, G. Clinical review: Breast development in trans women receiving cross-sex hormones. J. Sex. Med. 2014, 11, 1240–1247. [Google Scholar] [CrossRef]
- Gelles-Soto, D.; Ward, D.; Florio, T.; Kouzounis, K.; Salgado, C.J. Maximizing surgical outcomes with gender affirming hormone therapy in gender affirmation surgery. J. Clin. Transl. Endocrinol. 2024, 36, 100355. [Google Scholar] [CrossRef]
- Yang, X.; Wang, H.; Jiao, B. Mammary gland stem cells and their application in breast cancer. Oncotarget 2017, 8, 10675–10691. [Google Scholar] [CrossRef]
- Bondy, C.A.; Turner Syndrome Study, G. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J. Clin. Endocrinol. Metab. 2007, 92, 10–25. [Google Scholar] [CrossRef] [PubMed]
- Bahr, C.; Ewald, J.; Dragovich, R.; Gothard, M.D. Effects of progesterone on gender affirmation outcomes as part of feminizing hormone therapy. J. Am. Pharm. Assoc. 2024, 64, 268–272. [Google Scholar] [CrossRef] [PubMed]
- Nolan, B.J.; Frydman, A.S.; Leemaqz, S.Y.; Carroll, M.; Grossmann, M.; Zajac, J.D.; Cheung, A.S. Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: A prospective controlled study. Endocr. Connect. 2022, 11, e220170. [Google Scholar] [CrossRef] [PubMed]
- De Blok, C.J.M.; Dijkman, B.A.M.; Wiepjes, C.M.; Staphorsius, A.S.; Timmermans, F.W.; Smit, J.M.; Dreijerink, K.M.A.; den Heijer, M. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. J. Clin. Endocrinol. Metab. 2021, 106, e782–e790. [Google Scholar] [CrossRef]
- Dijkman, B.A.M.; Helder, D.; Boogers, L.S.; Gieles, N.C.; van Heesewijk, J.O.; Slaa, S.T.; Liberton, N.; Wiepjes, C.M.; de Blok, C.J.M.; den Heijer, M.; et al. Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: A randomized controlled trial. BMC Pharmacol. Toxicol. 2023, 24, 80. [Google Scholar] [CrossRef]
- Dijkman, B.A.M.; Blok, C.J.M.; Dreijerink, K.M.A.; Heijer, M.D. Progestin-related breast volume changes in a woman with complete androgen insensitivity syndrome (CAIS). Endocrinol. Diabetes Metab. Case Rep. 2023, 2023, 22-0346. [Google Scholar] [CrossRef]
- Boogers, L.S.; Sardo Infirri, S.A.; Bouchareb, A.; Dijkman, B.A.M.; Helder, D.; de Blok, C.J.M.; Liberton, N.; den Heijer, M.; van Trotsenburg, A.S.P.; Dreijerink, K.M.A.; et al. Variations in volume; Breast size in trans women in relation to timing of testosterone suppression. J. Clin. Endocrinol. Metab. 2024, dgae573. [Google Scholar] [CrossRef]
- Henderson, V.W. Progesterone and human cognition. Climacteric 2018, 21, 333–340. [Google Scholar] [CrossRef]
- Giannouli, V. Are sex differences in self-estimated intelligence an elusive phenomenon? Exploring the role of working memory, creativity, and other psychological correlates in young and older adults. Brain Behav. 2023, 13, e2857. [Google Scholar] [CrossRef]
- Reilly, D.; Neumann, D.L.; Andrews, G. Gender Differences in Self-Estimated Intelligence: Exploring the Male Hubris, Female Humility Problem. Front. Psychol. 2022, 13, 812483. [Google Scholar] [CrossRef]
- Trifu, S.; Vladuti, A.; Popescu, A. The Neuroendocrinological Aspects of Pregnancy and Postpartum Depression. Acta Endocrinol. 2019, 15, 410–415. [Google Scholar] [CrossRef]
- Kerckhof, M.E.; Kreukels, B.P.C.; Nieder, T.O.; Becker-Hebly, I.; van de Grift, T.C.; Staphorsius, A.S.; Kohler, A.; Heylens, G.; Elaut, E. Prevalence of Sexual Dysfunctions in Transgender Persons: Results from the ENIGI Follow-Up Study. J. Sex. Med. 2019, 16, 2018–2029. [Google Scholar] [CrossRef] [PubMed]
- Roney, J.R.; Simmons, Z.L. Hormonal predictors of sexual motivation in natural menstrual cycles. Horm. Behav. 2013, 63, 636–645. [Google Scholar] [CrossRef] [PubMed]
- Harry-Hernandez, S.; Reisner, S.L.; Schrimshaw, E.W.; Radix, A.; Mallick, R.; Callander, D.; Suarez, L.; Dubin, S.; Khan, A.; Duncan, D.T. Gender Dysphoria, Mental Health, and Poor Sleep Health Among Transgender and Gender Nonbinary Individuals: A Qualitative Study in New York City. Transgend. Health 2020, 5, 59–68. [Google Scholar] [CrossRef]
- Morssinkhof, M.W.L.; Wiepjes, C.M.; Bosman, B.W.; Kinds, J.; Fisher, A.D.; Greenman, Y.; Kreukels, B.P.C.; T’Sjoen, G.; van der Werf, Y.D.; Heijer, M.D.; et al. Sex hormones, insomnia, and sleep quality: Subjective sleep in the first year of hormone use in transgender persons. Sleep. Med. 2023, 107, 316–326. [Google Scholar] [CrossRef]
- Kalayjian, A.; Laszlo, K.; Fassler, M.; Schonrock, Z.; Delarose, K.E.; Ly, A.M.; English, C.D.; Cirrincione, L.R. Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy. J. Am. Pharm. Assoc. 2024, 64, 283–289.e282. [Google Scholar] [CrossRef]
- Reisman, T.; Goldstein, Z. Case Report: Induced Lactation in a Transgender Woman. Transgend. Health 2018, 3, 24–26. [Google Scholar] [CrossRef]
- Martin, C.R.; Ling, P.R.; Blackburn, G.L. Review of Infant Feeding: Key Features of Breast Milk and Infant Formula. Nutrients 2016, 8, 279. [Google Scholar] [CrossRef]
- Wamboldt, R.; Shuster, S.; Sidhu, B.S. Lactation Induction in a Transgender Woman Wanting to Breastfeed: Case Report. J. Clin. Endocrinol. Metab. 2021, 106, e2047–e2052. [Google Scholar] [CrossRef]
- Jin, X.; Perrella, S.L.; Lai, C.T.; Taylor, N.L.; Geddes, D.T. Causes of Low Milk Supply: The Roles of Estrogens, Progesterone, and Related External Factors. Adv. Nutr. 2024, 15, 100129. [Google Scholar] [CrossRef]
- Ikebukuro, S.; Tanaka, M.; Kaneko, M.; Date, M.; Tanaka, S.; Wakabayashi, H.; Murase, M.; Ninomiya, N.; Kamiya, T.; Ogawa, M.; et al. Induced lactation in a transgender woman: Case report. Int. Breastfeed. J. 2024, 19, 66. [Google Scholar] [CrossRef] [PubMed]
- Delgado, D.; Stellwagen, L.; McCune, S.; Sejane, K.; Bode, L. Experience of Induced Lactation in a Transgender Woman: Analysis of Human Milk and a Suggested Protocol. Breastfeed. Med. 2023, 18, 888–893. [Google Scholar] [CrossRef] [PubMed]
- Trahair, E.D.; Kokosa, S.; Weinhold, A.; Parnell, H.; Dotson, A.B.; Kelley, C.E. Novel Lactation Induction Protocol for a Transgender Woman Wishing to Breastfeed: A Case Report. Breastfeed. Med. 2024, 19, 301–305. [Google Scholar] [CrossRef] [PubMed]
- Van Amesfoort, J.E.; Van Mello, N.M.; van Genugten, R. Lactation induction in a transgender woman: Case report and recommendations for clinical practice. Int. Breastfeed. J. 2024, 19, 18. [Google Scholar] [CrossRef]
- Kim, Y.J. Pivotal roles of prolactin and other hormones in lactogenesis and the nutritional composition of human milk. Clin. Exp. Pediatr. 2020, 63, 312–313. [Google Scholar] [CrossRef]
- Bosland, M.C. The role of estrogens in prostate carcinogenesis: A rationale for chemoprevention. Rev. Urol. 2005, 7 (Suppl. S3), S4–S10. [Google Scholar]
- Croxatto, H.B.; Diaz, S.; Peralta, O.; Juez, G.; Casado, M.E.; Salvatierra, A.M.; Duran, E. Fertility regulation in nursing women. II. Comparative performance of progesterone implants versus placebo and copper T. Am. J. Obstet. Gynecol. 1982, 144, 201–208. [Google Scholar] [CrossRef]
- Sharif, A.; Malhotra, N.R.; Acosta, A.M.; Kajdacsy-Balla, A.A.; Bosland, M.; Guzman, G.; Prins, G.S.; Abern, M.R. The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? Prostate 2017, 77, 824–828. [Google Scholar] [CrossRef]
- Ingham, M.D.; Lee, R.J.; MacDermed, D.; Olumi, A.F. Prostate cancer in transgender women. Urol. Oncol. 2018, 36, 518–525. [Google Scholar] [CrossRef]
- Joint, R.; Chen, Z.E.; Cameron, S. Breast and reproductive cancers in the transgender population: A systematic review. BJOG 2018, 125, 1505–1512. [Google Scholar] [CrossRef]
- Silveira, P.C.; Ip, I.K.; Goldhaber, S.Z.; Piazza, G.; Benson, C.B.; Khorasani, R. Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. JAMA Intern. Med. 2015, 175, 1112–1117. [Google Scholar] [CrossRef] [PubMed]
- LaVasseur, C.; Neukam, S.; Kartika, T.; Samuelson Bannow, B.; Shatzel, J.; DeLoughery, T.G. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res. Pract. Thromb. Haemost. 2022, 6, e12763. [Google Scholar] [CrossRef] [PubMed]
- Canonico, M.; Scarabin, P.Y. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Climacteric 2009, 12 (Suppl. S1), 76–80. [Google Scholar] [CrossRef] [PubMed]
- Douketis, J.D.; Julian, J.A.; Kearon, C.; Anderson, D.R.; Crowther, M.A.; Bates, S.M.; Barone, M.; Piovella, F.; Turpie, A.G.; Middeldorp, S.; et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J. Thromb. Haemost. 2005, 3, 943–948. [Google Scholar] [CrossRef]
- Canonico, M.; Oger, E.; Plu-Bureau, G.; Conard, J.; Meyer, G.; Levesque, H.; Trillot, N.; Barrellier, M.T.; Wahl, D.; Emmerich, J.; et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007, 115, 840–845. [Google Scholar] [CrossRef]
- Chan, W.; Drummond, A.; Kelly, M. Deep vein thrombosis in a transgender woman. CMAJ 2017, 189, E502–E504. [Google Scholar] [CrossRef]
- Boskey, E.R.; Taghinia, A.H.; Ganor, O. Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review. JAMA Surg. 2019, 154, 159–169. [Google Scholar] [CrossRef]
- De Barros, V.; de Oliveira, A.; do Nascimento, D.J.; Zlotnik, E.; Teruchkin, M.M.; Marques, M.A.; Margarido, P.F.R. Use of hormones and risk of venous thromboembolism. Rev. Bras. Ginecol. Obstet. 2024, 46, e-FPS02. [Google Scholar] [CrossRef]
- De Blok, C.J.M.; Wiepjes, C.M.; Nota, N.M.; van Engelen, K.; Adank, M.A.; Dreijerink, K.M.A.; Barbe, E.; Konings, I.; den Heijer, M. Breast cancer risk in transgender people receiving hormone treatment: Nationwide cohort study in the Netherlands. BMJ 2019, 365, l1652. [Google Scholar] [CrossRef]
- Coelingh Bennink, H.J.T.; Egberts, J.F.M.; Mol, J.A.; Roes, K.C.B.; van Diest, P.J. Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function. J. Clin. Endocrinol. Metab. 2020, 105, e3065–e3074. [Google Scholar] [CrossRef]
- Coelingh Bennink, H.J.T.; Schultz, I.J.; Schmidt, M.; Jordan, V.C.; Briggs, P.; Egberts, J.F.M.; Gemzell-Danielsson, K.; Kiesel, L.; Kluivers, K.; Krijgh, J.; et al. Progesterone from ovulatory menstrual cycles is an important cause of breast cancer. Breast Cancer Res. 2023, 25, 60. [Google Scholar] [CrossRef] [PubMed]
- Hartley, R.L.; Stone, J.P.; Temple-Oberle, C. Breast cancer in transgender patients: A systematic review. Part 1: Male to female. Eur. J. Surg. Oncol. 2018, 44, 1455–1462. [Google Scholar] [CrossRef] [PubMed]
- Sonnenblick, E.B.; Shah, A.D.; Goldstein, Z.; Reisman, T. Breast Imaging of Transgender Individuals: A Review. Curr. Radiol. Rep. 2018, 6, 1. [Google Scholar] [CrossRef]
- Kranz, G.S.; Hahn, A.; Kaufmann, U.; Kublbock, M.; Hummer, A.; Ganger, S.; Seiger, R.; Winkler, D.; Swaab, D.F.; Windischberger, C.; et al. White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. J. Neurosci. 2014, 34, 15466–15475. [Google Scholar] [CrossRef]
- Seiger, R.; Hahn, A.; Hummer, A.; Kranz, G.S.; Ganger, S.; Woletz, M.; Kraus, C.; Sladky, R.; Kautzky, A.; Kasper, S.; et al. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. Psychoneuroendocrinology 2016, 74, 371–379. [Google Scholar] [CrossRef]
- Handschuh, P.A.; Reed, M.B.; Murgas, M.; Vraka, C.; Kaufmann, U.; Nics, L.; Klobl, M.; Ozenil, M.; Konadu, M.E.; Patronas, E.M.; et al. Effects of gender-affirming hormone therapy on gray matter density, microstructure and monoamine oxidase A levels in transgender subjects. Neuroimage 2024, 297, 120716. [Google Scholar] [CrossRef]
- Aghi, K.; Goetz, T.G.; Pfau, D.R.; Sun, S.E.D.; Roepke, T.A.; Guthman, E.M. Centering the Needs of Transgender, Nonbinary, and Gender-Diverse Populations in Neuroendocrine Models of Gender-Affirming Hormone Therapy. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2022, 7, 1268–1279. [Google Scholar] [CrossRef]
- Sacco, S.; Ricci, S.; Degan, D.; Carolei, A. Migraine in women: The role of hormones and their impact on vascular diseases. J. Headache Pain. 2012, 13, 177–189. [Google Scholar] [CrossRef]
- Martinez, C.I.; Liktor-Busa, E.; Largent-Milnes, T.M. Molecular mechanisms of hormones implicated in migraine and the translational implication for transgender patients. Front. Pain Res. 2023, 4, 1117842. [Google Scholar] [CrossRef]
- Ahmad, S.R.; Rosendale, N. Sex and Gender Considerations in Episodic Migraine. Curr. Pain. Headache Rep. 2022, 26, 505–516. [Google Scholar] [CrossRef]
- Astarita, C.; D’Angelo-Maansson, B.; Massaro-Giordano, M.; Alba, M.P.; Boffo, S.; Macchi, I.; Giordano, A.; Macaluso, M. Effect of sex steroid hormone fluctuations in the pathophysiology of male-retinal pigment epithelial cells. J. Cell Physiol. 2018, 233, 6965–6974. [Google Scholar] [CrossRef] [PubMed]
- Jackson Cullison, S.R.; Jedrych, J.J.; James, A.J. Porphyria cutanea tarda unmasked by supratherapeutic estrogen during gender-affirming hormone therapy. JAAD Case Rep. 2020, 6, 675–678. [Google Scholar] [CrossRef] [PubMed]
- Ferraro, J.J.; Reynolds, A.; Edoigiawerie, S.; Seu, M.Y.; Horen, S.R.; Aminzada, A.; Hamidian Jahromi, A. Impact of gender-affirming hormone therapy on the development of COVID-19 infections and associated complications: A systematic review. World J. Methodol. 2022, 12, 465–475. [Google Scholar] [CrossRef] [PubMed]
- Masterson, J.M.; Bui, C.; Zhang, Y.; Yuan, X.; Huynh, C.; Jawanda, H.; Hasan, W.; Tourtellotte, W.; Luthringer, D.; Garcia, M.M. Feminising hormone therapy reduces testicular ACE-2 receptor expression: Implications for treatment or prevention of COVID-19 infection in men. Andrologia 2021, 53, e14186. [Google Scholar] [CrossRef]
- Handgraaf, S.; Philippe, J. The Role of Sexual Hormones on the Enteroinsular Axis. Endocr. Rev. 2019, 40, 1152–1162. [Google Scholar] [CrossRef]
- Santos, M.P.; Cauduro, L.F.R.; Ferreira, M.M.; Martucci, L.F.; Vecchiatto, B.; Vilas-Boas, E.A.; Americo, A.L.V.; Pereira, R.O.; Rogero, M.M.; Fiorino, P.; et al. Effect of Low-Dose Progesterone on Glycemic Metabolism, Morphology and Function of Adipose Tissue and Pancreatic Islets in Diet-Induced Obese Female Mice. Front. Biosci. 2023, 28, 312. [Google Scholar] [CrossRef]
- Tselovalnikova, T.; Fatima, I.; Barthel, B. Gender-Affirming Hormone Therapy With Estrogen Causing Gallstone Associated Acute Pancreatitis. AACE Clin. Case Rep. 2024, 10, 210–213. [Google Scholar] [CrossRef]
- Toyoda, Y.; Endo, S.; Tsuneyama, K.; Miyashita, T.; Yano, A.; Fukami, T.; Nakajima, M.; Yokoi, T. Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Toxicol. Sci. 2012, 126, 16–27. [Google Scholar] [CrossRef]
- Xu, L.; Yuan, Y.; Che, Z.; Tan, X.; Wu, B.; Wang, C.; Xu, C.; Xiao, J. The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones. Front. Immunol. 2022, 13, 939631. [Google Scholar] [CrossRef]
- Togioka, B.M.; Harriman, K.A.; Ye, S.; Berli, J. Frequency and Characteristics of Postoperative Neuropathy in Individuals on Gender-Affirming Hormone Therapy Undergoing Gender Affirmation Surgery: A Retrospective Cohort Study. Cureus 2023, 15, e47988. [Google Scholar] [CrossRef]
- Stelmar, J.; Victor, R.; Yuan, N.; Smith, S.M.; Mallavarapu, S.; Sandhu, S.; Garcia, M.M. Endocrine, gender dysphoria, and sexual function benefits of gender-affirming bilateral orchiectomy: Patient outcomes and surgical technique. Sex. Med. 2024, 12, qfae048. [Google Scholar] [CrossRef] [PubMed]
- Moghadam, S.; Roca, Y.; LaGuardia, J.S.; Huang, K.X.; Chin, M.G.; Bedar, M.; Fadich, S.K.; Lee, J.C. Effect of Duration of Feminizing Hormone Therapy on Facial Fat Volumes—PubMed. Plast. Reconstr. Surg. 2024, 154, 1081–1088. [Google Scholar] [CrossRef] [PubMed]
- Angus, L.M.; Lin, T.; Leemaqz, S.Y.; Cheung, A.S. Effect of Feminizing Hormone Therapy on QTc Interval: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw. Open 2024, 7, e243994. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szymczyk, S.; Mączka, K.; Mądrzak, L.; Grymowicz, M.; Smolarczyk, R. The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population—A Narrative Review. J. Clin. Med. 2024, 13, 6795. https://doi.org/10.3390/jcm13226795
Szymczyk S, Mączka K, Mądrzak L, Grymowicz M, Smolarczyk R. The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population—A Narrative Review. Journal of Clinical Medicine. 2024; 13(22):6795. https://doi.org/10.3390/jcm13226795
Chicago/Turabian StyleSzymczyk, Simone, Katarzyna Mączka, Lidia Mądrzak, Monika Grymowicz, and Roman Smolarczyk. 2024. "The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population—A Narrative Review" Journal of Clinical Medicine 13, no. 22: 6795. https://doi.org/10.3390/jcm13226795
APA StyleSzymczyk, S., Mączka, K., Mądrzak, L., Grymowicz, M., & Smolarczyk, R. (2024). The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population—A Narrative Review. Journal of Clinical Medicine, 13(22), 6795. https://doi.org/10.3390/jcm13226795